188 related articles for article (PubMed ID: 10037247)
21. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
Biermasz NR; van Dulken H; Roelfsema F
J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
[TBL] [Abstract][Full Text] [Related]
22. Effects of GH assay standardization on evaluation of treatment outcomes for acromegaly in Japan.
Fukuda I; Kurimoto M; Tanaka S; Yamakado Y; Muraoka T; Takano K; Hizuka N
Endocr J; 2011; 58(9):777-82. PubMed ID: 21720049
[TBL] [Abstract][Full Text] [Related]
23. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
24. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels.
Feelders RA; Bidlingmaier M; Strasburger CJ; Janssen JA; Uitterlinden P; Hofland LJ; Lamberts SW; van der Lely AJ; de Herder WW
J Clin Endocrinol Metab; 2005 Dec; 90(12):6480-9. PubMed ID: 16159936
[TBL] [Abstract][Full Text] [Related]
25. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0.4 µg/L but < 1 µg/L.
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2017; 61(5):426-431. PubMed ID: 28977166
[TBL] [Abstract][Full Text] [Related]
27. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
[TBL] [Abstract][Full Text] [Related]
28. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
[TBL] [Abstract][Full Text] [Related]
29. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
Minniti G; Jaffrain-Rea ML; Osti M; Esposito V; Santoro A; Solda F; Gargiulo P; Tamburrano G; Enrici RM
Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
[TBL] [Abstract][Full Text] [Related]
30. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
31. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
Sheaves R; Jenkins P; Blackburn P; Huneidi AH; Afshar F; Medbak S; Grossman AB; Besser GM; Wass JA
Clin Endocrinol (Oxf); 1996 Oct; 45(4):407-13. PubMed ID: 8959078
[TBL] [Abstract][Full Text] [Related]
32. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
33. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
[TBL] [Abstract][Full Text] [Related]
34. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
35. Elevated IGF-1 with GH suppression after an oral glucose overload: incipient acromegaly or false-positive IGF-1?
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2016; 60(6):510-514. PubMed ID: 27982199
[TBL] [Abstract][Full Text] [Related]
36. GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disorders.
Verrua E; Filopanti M; Ronchi CL; Olgiati L; Ferrante E; Giavoli C; Sala E; Mantovani G; Arosio M; Beck-Peccoz P; Lania AG; Spada A
J Clin Endocrinol Metab; 2011 Jan; 96(1):E83-8. PubMed ID: 20962023
[TBL] [Abstract][Full Text] [Related]
37. No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study).
Ku CR; Choe EY; Hong JW; Kim EH; Park SH; Kim SH; Lee EJ
Medicine (Baltimore); 2016 Jun; 95(24):e3808. PubMed ID: 27310957
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
Díez JJ; Iglesias P; Gómez-Pan A
J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
[TBL] [Abstract][Full Text] [Related]
39. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
40. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
Lissett CA; Peacey SR; Laing I; Tetlow L; Davis JR; Shalet SM
Clin Endocrinol (Oxf); 1998 Nov; 49(5):653-7. PubMed ID: 10197082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
